Levodopa in the treatment of Parkinson’s disease
Identifieur interne : 000A48 ( Main/Exploration ); précédent : 000A47; suivant : 000A49Levodopa in the treatment of Parkinson’s disease
Auteurs : A. H. V. Schapira [Royaume-Uni] ; M. Emre [Turquie] ; P. Jenner [Royaume-Uni] ; Werner Poewe [Autriche]Source :
- European Journal of Neurology [ 1351-5101 ] ; 2009-09.
English descriptors
- KwdEn :
Abstract
The predominant motor features of Parkinson’s disease (PD) are caused by degeneration of dopaminergic neurones and can be reversed in part or whole by dopamine replacement or augmentation strategies. Physicians have most experience with the use of levodopa, which remains the most potent oral dopaminergic treatment for PD. There are reservations about the long‐term use of levodopa, most particularly in the context of its propensity to induce motor fluctuations and dyskinesias. Strategies exist to delay or diminish these complications, but the physician must lay the basis for these in the selection of drugs for early treatment and the sequence of drugs introduced subsequently. Levodopa efficacy and duration of effect may be enhanced by combination with a catechol‐O‐methyl transferase inhibitor. Maintaining good motor function and quality of life remain the primary goals of therapy and the principle that treatment must be tailored to the individual patient’s needs is paramount.
Url:
DOI: 10.1111/j.1468-1331.2009.02697.x
Affiliations:
- Autriche, Royaume-Uni, Turquie
- Angleterre, Grand Londres, Tyrol (Land)
- Innsbruck, Londres
- Université de médecine d'Innsbruck
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa in the treatment of Parkinson’s disease</title><author><name sortKey="Schapira, A H V" sort="Schapira, A H V" uniqKey="Schapira A" first="A. H. V." last="Schapira">A. H. V. Schapira</name></author><author><name sortKey="Emre, M" sort="Emre, M" uniqKey="Emre M" first="M." last="Emre">M. Emre</name></author><author><name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P." last="Jenner">P. Jenner</name></author><author><name sortKey="Poewe, W" sort="Poewe, W" uniqKey="Poewe W" first="W." last="Poewe">Werner Poewe</name><affiliation><country>Autriche</country><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6FA11665A1F5FE986D3C112CF38E544CBB832384</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1111/j.1468-1331.2009.02697.x</idno><idno type="url">https://api.istex.fr/document/6FA11665A1F5FE986D3C112CF38E544CBB832384/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000B78</idno><idno type="wicri:Area/Main/Curation">000A32</idno><idno type="wicri:Area/Main/Exploration">000A48</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Levodopa in the treatment of Parkinson’s disease</title><author><name sortKey="Schapira, A H V" sort="Schapira, A H V" uniqKey="Schapira A" first="A. H. V." last="Schapira">A. H. V. Schapira</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neurosciences, Institute of Neurology, University College London, National Hospital for Neurology and Neurosurgery and Royal Free Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Emre, M" sort="Emre, M" uniqKey="Emre M" first="M." last="Emre">M. Emre</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Istanbul Medical School, Istanbul Tip Fak, Noroloji A.B.D., Capa Istanbul</wicri:regionArea><wicri:noRegion>Capa Istanbul</wicri:noRegion></affiliation></author><author><name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P." last="Jenner">P. Jenner</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King’s College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Poewe, W" sort="Poewe, W" uniqKey="Poewe W" first="W." last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>University Hospital Innsbruck, Vorstand D. Univ‐Klinik F Neurologie, Innsbruck</wicri:regionArea><wicri:noRegion>Innsbruck</wicri:noRegion><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Neurology</title><idno type="ISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2009-09">2009-09</date><biblScope unit="volume">16</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="982">982</biblScope><biblScope unit="page" to="989">989</biblScope></imprint><idno type="ISSN">1351-5101</idno></series><idno type="istex">6FA11665A1F5FE986D3C112CF38E544CBB832384</idno><idno type="DOI">10.1111/j.1468-1331.2009.02697.x</idno><idno type="ArticleID">ENE2697</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1351-5101</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson’s disease</term><term>catechol‐O‐methyl transferase inhibitor</term><term>dopamine</term><term>dopamine agonist</term><term>levodopa</term><term>monoamine oxidase B inhibitor</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The predominant motor features of Parkinson’s disease (PD) are caused by degeneration of dopaminergic neurones and can be reversed in part or whole by dopamine replacement or augmentation strategies. Physicians have most experience with the use of levodopa, which remains the most potent oral dopaminergic treatment for PD. There are reservations about the long‐term use of levodopa, most particularly in the context of its propensity to induce motor fluctuations and dyskinesias. Strategies exist to delay or diminish these complications, but the physician must lay the basis for these in the selection of drugs for early treatment and the sequence of drugs introduced subsequently. Levodopa efficacy and duration of effect may be enhanced by combination with a catechol‐O‐methyl transferase inhibitor. Maintaining good motor function and quality of life remain the primary goals of therapy and the principle that treatment must be tailored to the individual patient’s needs is paramount.</div></front></TEI><affiliations><list><country><li>Autriche</li><li>Royaume-Uni</li><li>Turquie</li></country><region><li>Angleterre</li><li>Grand Londres</li><li>Tyrol (Land)</li></region><settlement><li>Innsbruck</li><li>Londres</li></settlement><orgName><li>Université de médecine d'Innsbruck</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Schapira, A H V" sort="Schapira, A H V" uniqKey="Schapira A" first="A. H. V." last="Schapira">A. H. V. Schapira</name></region><name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P." last="Jenner">P. Jenner</name></country><country name="Turquie"><noRegion><name sortKey="Emre, M" sort="Emre, M" uniqKey="Emre M" first="M." last="Emre">M. Emre</name></noRegion></country><country name="Autriche"><region name="Tyrol (Land)"><name sortKey="Poewe, W" sort="Poewe, W" uniqKey="Poewe W" first="W." last="Poewe">Werner Poewe</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A48 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A48 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:6FA11665A1F5FE986D3C112CF38E544CBB832384
|texte= Levodopa in the treatment of Parkinson’s disease
}}
| This area was generated with Dilib version V0.6.23. |  |